Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)

Oncology
1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

HB
HaiHe BiopharmaChina - Shanghai
1 program
1
HH2853 TabletsPhase 1/21 trial
Active Trials
NCT06909877RecruitingEst. Jul 2027

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
2027
HaiHe BiopharmaHH2853 Tablets

Clinical Trials (1)

NCT06909877HaiHe BiopharmaHH2853 Tablets

Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma

Start: Jul 2022Est. completion: Jul 2027
Phase 1/2Recruiting

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
4m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
4m ago

Office Administrator

SystImmune
4m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
15m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
18m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
18m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials
1 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)